PLUS1
640.63
0.00 (0.0%)
0.00 (0.0%)
Upgrade to Real-Time
Afterhours (Closed)
Best deals to access real time data! |
|
Big Cap Pro
Monthly Subscription
for only
|
|
Small Cap Basic
Monthly Subscription
for only
|
|
Real-Time Alerts for Volume Breakouts, Highs and Lows for NYSE, NASDAQ, Amex, OTC Markets and OTCBB
Monthly Subscription
for only
|
|
VAT not included
|
| Company Name | Stock Ticker Symbol | Market | Type |
|---|---|---|---|
| Regeneron Pharmaceuticals Inc | REGN | NASDAQ | Common Stock |
| Price Change | Change Percent | Stock Price | Low Price | High Price | Open Price | Close Price | Last Traded  |
|
|---|---|---|---|---|---|---|---|---|
| 0.00 | 0.0% | 640.63 | 0.00 | 0.00 | 0.00 | 640.63 | 20:00:00 |
| Bid Price | Ask Price | Spread | Spread % | News | |
|---|---|---|---|---|---|
| 635.50 | 640.63 | 5.13 | 0.8% | - | - |
| Last Trade Time | Type | Quantity | Stock Price | Currency |
|---|---|---|---|---|
| - | 0 | $ 640.63 | USD |
Regeneron Pharmaceuticals Financials
| Market Cap | Shares in Issue | Float | Revenue | Profit/Loss | EPS | PE Ratio |
|---|---|---|---|---|---|---|
| $ 65.73B | 102.60M | 100.79M | $ 7.86B | $ 2.70B | 18.45 | 30.60 |
| Short Interest | Dividends Per Share | Dividend Yield | Ex-Div Date | Insider B/S | Insider % Owned |
|---|---|---|---|---|---|
| - | $ - | 0.00% | - | - |
Regeneron Pharmaceuticals News
| Date | Time | Source | News Article |
|---|---|---|---|
| 7/08/2020 | 16:30 | PR Newswire (US) | Regeneron to Report Second Quarter 2020 Financial and.. |
| 7/08/2020 | 16:23 | Edgar (US Regulatory) | Statement of Changes in Beneficial Ownership (4) |
| 7/08/2020 | 16:20 | Edgar (US Regulatory) | Statement of Changes in Beneficial Ownership (4) |
| 7/07/2020 | 12:30 | Dow Jones News | U.S. Commits $2 Billion for Covid-19 Vaccine, Drug Supplies.. |
| 7/07/2020 | 10:59 | Dow Jones News | U.S. Commits $2 Billion for Covid-19 Vaccine, Drug Supplies |
| 7/07/2020 | 07:44 | Dow Jones News | Regeneron Gets Federal Manufacturing Contract for Covid-19.. |
| 7/07/2020 | 07:29 | Edgar (US Regulatory) | Current Report Filing (8-k) |
|
|
{{bbMessage.M_Alias}} {{bbMessage.MSG_Date}} {{bbMessage.HowLongAgo}} {{bbMessage.MSG_ID}} {{bbMessage.MSG_Subject}} |
Loading Messages....
Historical REGN Price Data
| Period † | Open | High | Low | VWAP | Avg. Daily Vol | Change | % |
|---|---|---|---|---|---|---|---|
| 1 Week | 635.00 | 655.9255 | 623.50 | 637.27 | 1,014,896 | 5.63 | 0.89% |
| 1 Month | 616.01 | 655.9255 | 575.89 | 619.90 | 1,001,220 | 24.62 | 4.0% |
| 3 Months | 549.99 | 655.9255 | 507.69 | 583.32 | 1,370,530 | 90.64 | 16.48% |
| 6 Months | 384.62 | 655.9255 | 328.125 | 509.72 | 1,323,896 | 256.01 | 66.56% |
| 1 Year | 308.15 | 655.9255 | 271.37 | 441.72 | 1,013,731 | 332.48 | 107.9% |
| 3 Years | 497.61 | 655.9255 | 271.37 | 400.67 | 860,668 | 143.02 | 28.74% |
| 5 Years | 514.50 | 655.9255 | 271.37 | 411.74 | 849,789 | 126.13 | 24.52% |
Regeneron Pharmaceuticals Description
| Regeneron Pharmaceuticals discovers, develops, and commercializes products that fight eye disease, cardiovascular disease, cancer, and inflammation. The company has six marketed products: Eylea, approved for wet age-related macular degeneration and other eye diseases; Praluent for LDL cholesterol lowering; Zaltrap in colorectal cancer; Dupixent in atopic dermatitis, asthma, and nasal polyposis; Libtayo in cutaneous squamous cell carcinoma; Arcalyst in CAPS; and Kevzara in rheumatoid arthritis. Regeneron is also developing monoclonal antibodies with Sanofi in immunology and cancer. |
